Showing 4511-4520 of 6036 results for "".
- Iveric Bio Completes Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophyhttps://modernod.com/news/iveric-bio-announces-completion-of-rolling-nda-submission-to-fda-for-avacincaptad-pegol-for-the-treatment-of-geographic-atrophy/2481305/Iveric Bio announced that it has submitted to the FDA the third and final part of its new drug application (NDA) for rolling review of avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degen
- Elios Vision Announces Registration of Elios in Francehttps://modernod.com/news/elios-vision-announces-registration-of-elios-in-france/2481304/Elios Vision announced that its Elios technology, which is used to treat glaucoma at the same time as cataract surgery, is now registered in France. Elios does not require an implant and is designed to provide long-lasting results that may free patients from drop therapy.
- New Genetic Mutation Behind Childhood Glaucoma Identifiedhttps://modernod.com/news/new-genetic-mutation-behind-childhood-glaucoma-identified/2481303/An international team led by Harvard Medical School scientists at Mass Eye and Ear and Boston Children’s Hospital has discovered a new genetic mutation that may be a root cause of severe cases of childhood glaucoma, according to a Harvard Medical School research
- Staar Surgical CEO Caren Mason to Retire; Tom Frinzi Appointed New CEOhttps://modernod.com/news/staar-surgical-ceo-caren-mason-to-retire-tom-frinzi-appointed-new-ceo/2481302/Staar Surgical announced that President and Chief Executive Officer Caren Mason will be retiring December 31, 2022, after serving in that postion for 7 years. Staar's Board of Directors has appointed ophthalmic industry executive Thomas G. Frinzi, current Board Chair of Staar,
- AI-Diagnostics Startup Altris AI Raises $1 Million to Scale AI-Based Eye Care Diagnostics Platformhttps://modernod.com/news/ai-diagnostics-startup-altris-ai-raises-1-million/2481296/Altris AI announced it has raised $1 million to scale its AI-enabled eye care diagnostics solution. Altris AI, which is a US-based startup originally from Ukraine, developed a SaaS platform based on 5 million OCT scans that detected and interpreted more than 100 pathologies an
- NovaSight Announces Commercial Release of CureSight in the US; Names a New VP of Sales & Marketinghttps://modernod.com/news/novasight-introduces-curesight-to-the-us-and-names-a-new-vp-of-sales-marketing/2481295/NovaSight has announced that its CureSight digital therapy for amblyopia will be released to the US market beginning this month. CureSight received FDA 510(K) clearance based on a pivotal study that found the device to be noninferior to eye patching—t
- Harrow Enters Into Agreement to Acquire Exclusive US Rights to Five Ophthalmic Products from Novartishttps://modernod.com/news/harrow-enters-into-agreement-to-acquire-exclusive-us-rights-to-five-ophthalmic-products-from-novartis/2481292/Harrow announced it has entered into a agreement for the acquisition of the exclusive US commercial rights to five FDA‑approved ophthalmic products from Novartis in a deal worth up to $175 million. This transaction, which is the second acquisition transaction between Har
- Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi for In-Office Pupil Dilationhttps://modernod.com/news/eyenovia-announces-fda-acceptance-of-new-drug-application-for-mydcombi-for-in-office-pupil-dilation/2481289/Eyenovia announced that the FDA has accepted for review the company’s new drug application (NDA) for MydCombi ophthalmic spray. MydCombi is a drug-device combination product that comprises the company’s proprietary, first-in-class combination of tropicamide and phe
- Nidek Launches Fully Assisted Refraction System for TS-610https://modernod.com/news/nidek-launches-fully-assisted-refraction-system-for-ts-610/2481287/Nidek has announced the launch of the Fully Assisted Refraction System (FARS), an optional kit for the TS-610 Nidek Tabletop Refraction System. allowing for subjective refractions that integrate the chart and refractor into a single unit. FARS is used to determine th
- CORD Files for Premarket Approval with the FDA for the SC9 IOL for Cataract Surgeryhttps://modernod.com/news/cord-files-for-premarket-approval-with-the-fda-for-the-sc9-iol-for-cataract-surgery/2481284/Cumming Ophthalmic Research and Development (CORD) announced that it has submitted a premarket approval (PMA) application to the FDA for the Model SC9 IOL. The SC9 is the brainchild of Stuart Cumming, MD, FACS, FRCOphth, who has over one hundred patents related to IOLs. D